NEW YORK, Sept. 11, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Endo International plc (NASDAQ:ENDP) between November 30, 2012 and July 6, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Bier v. Endo International plc, et al. (Case No. 2:17-cv-03711-TJS) in the USDC for the Eastern District of Pennsylvania. Click here to view the complaint. To get more information go to:
http://www.zlk.com/pslra-sbm/endo-international-plc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose material information regarding the Company’s branded pharmaceutical Opana ER. In particular, the complaint alleges that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Reformulated Opana was not resistant to crushing; (2) Reformulated Opana was not abuse-deterrent and its use carried an inherent risk of abuse by grinding, snorting, or injecting; (3) Reformulated Opana was contributing to an opioid public health crisis; and (4) Endo would ultimately remove Reformulated Opana from the market.
If you suffered a loss in Endo you have until October 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Samsung Electronics Shares Jump on HBM4 Mass Production Report
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



